The Regulation of Th1 Responses by the p38 MAPK

Ziyan Yang, Xia Zhang, Patricia A. Darrah and David M. Mosser

*J Immunol* 2010; 185:6205-6213; Prepublished online 11 October 2010;
doi: 10.4049/jimmunol.1000243
http://www.jimmunol.org/content/185/10/6205

References
This article cites 40 articles, 15 of which you can access for free at:
http://www.jimmunol.org/content/185/10/6205.full#ref-list-1

Why *The JI*? Submit online.
- Rapid Reviews! 30 days* from submission to initial decision
- No Triage! Every submission reviewed by practicing scientists
- Fast Publication! 4 weeks from acceptance to publication

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
The Regulation of Th1 Responses by the p38 MAPK

Ziyan Yang,*† Xia Zhang,*† Patricia A. Darrah,‡ and David M. Mosser*†

IL-12 is a dimeric cytokine that is produced primarily by APCs. In this study we examined the role that the p38 MAPKs (MAPK/p38) play in regulating IL-12 production. We show that inhibition of p38 dramatically increased IL-12 production upon stimulation, while decreasing TNF-α. This reciprocal effect on these two cytokines following MAPK/p38 inhibition occurred in many different APCs, following a variety of different stimuli. IL-12 production was also increased in macrophages treated with small interfering RNA to limit p38α expression, and in macrophages deficient in MKK3, a kinase upstream of p38. The increase in IL-12 production following MAPK/p38 inhibition appears to be due to enhanced IL-12 (p40) mRNA stability. We show that MAPK/p38 inhibition can promote Th1 immune responses and thereby enhance vaccine efficacy against leishmaniasis. In a mouse model of Leishmania major infection, vaccination with heat-killed L. major plus CpG and SB203580 elicited complete protection against infection compared with heat-killed L. major plus CpG without SB203580. Thus, this work suggests that MAPK/p38 inhibitors may be applied as adjuvants to bias immune responses and improve vaccinations against intracellular pathogens. The Journal of Immunology, 2010, 185: 6205–6213.

Interleukin-12 is a 70-kDa cytokine and the “founding member” of a small number of heterodimeric cytokines. IL-12p70 is composed of two covalently linked subunits, p35 and p40, which are encoded by two separated genes. APCs, particularly dendritic cells (DCs) and activated macrophages, are the main producers of IL-12 (1). IL-23, another heterodimeric cytokine with overlapping but distinct biological function from IL-12, consists of a p19 subunit paired with the common p40 subunit. Both of these cytokines can induce IFN-γ production from T cells (2). Both IL-12 and IL-23 production are controlled mainly at the level of p40 gene expression, despite the fact that this subunit is made in vast excess of the other subunits. The p40 subunit can associate with either p35 or p19 to form a heterodimer, or it can remain in solution as a monomer. p40 subunits have been reported to form homodimers that can bind to the murine IL-12R and antagonize IL-12p70 binding/signaling in vitro (3); however, the physiological relevance of these homodimers, particularly in human immune responses, is questionable (1, 4). The IFN-γ that is produced in response to IL-12 or IL-23 is largely responsible for the proinflammatory activity of these cytokines. Therefore, the proper regulation of p40-containing cytokines is critical to maintaining effective immunity but also preventing autoimmune pathology. Mice deficient in IL-12p40 show deficient Th1 development with reduced delayed-type hypersensitivity responses and NK cell responses (1).

The MAPKs play important roles in many cellular processes, including growth, differentiation, apoptosis, and the immune response (5, 6). Four major MAPK pathways have been identified in mammalian cells, ERK, p38, JNK, and ERK5. The p38 pathway is associated with cytokine production, inflammation, cell growth and differentiation, and cell death. This pathway is strongly activated by inflammatory cytokines such as IL-1 and TNF-α and also by environmental stress. The p38 pathway consists of several MAPKKKs, including MKKs 1–4, two MAPKKs, MKK3 and MKK6, and the four p38 isoforms, α, β, γ, and δ. Both p38α and p38β are ubiquitously expressed, whereas p38γ is expressed in skeletal muscle, and p38δ gene expression is found primarily in the lung, kidney, testis, pancreas, and small intestine. MKK3 and MKK6 exhibit high enzymatic specificity toward the p38 MAPK. MKK3 preferentially targets the p38α and p38β, whereas MKK6 can activate all p38 isoforms. Downstream substrates for p38 kinases include nuclear kinases MAPKAPK-2 (MK2), MSK1/2, and MNK, as well as transcription factors ATF-1/2, CHOP, MEF2, Elk-1, NF-κB, and p53 (6). Some studies suggest that p38 is required for both Th1 and Th2 differentiation as well as IFN-γ production (7). The p38 kinases can regulate cytokine production at the level of transcription (IFN-γ) or by stabilizing mRNAs (TNF-α) (8, 9).

Leishmaniasis is a worldwide disease with an estimated 12 million people infected throughout 88 countries (10). Effective primary immunity against Leishmania spp. requires IL-12-dependent production of IFN-γ from T cells. In animal studies, mice deficient in IL-12 are more susceptible to leishmaniasis (11), and the administration of rIL-12 to mice enables them to resolve Leishmania infection (12). The role of the MAPK/p38 pathway on the regulation of Leishmania infection has not been fully explored (13). In the present study, we investigated the role of p38 activation by different TLR agonists on IL-12 production in bone marrow-derived macrophages (BMMφs) and DCs. Our results demonstrate that the inhibition of p38 activation resulted in enhanced IL-12p40 and IL-12p70 production. The increase in IL-12p40 gene expression following p38 inhibition was primarily controlled at the level of mRNA stability. We further demonstrate that inhibition of p38 activation in APCs preferentially induced Th1 responses, and thereby enhanced vaccination against Leishmania major. Our results suggest that the activation of MAPK/p38 in APCs can limit Th1 immune responses, and that this pathway can be targeted to enhance cell-mediated immunity.
Materials and Methods

Mice, BMMDs, and bone marrow-derived DCs

BALB/c and C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA). IL-10 knockout mice on the BALB/c background, Mkk3 knockout mice on the C57BL6 background, and D011.10 mice on the BALB/c background were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were maintained in high efficiency particle control (HEPC) units (Thoren Caging SwineCenter, Hazleton, PA) of the University of Maryland. All animal studies were reviewed and approved by the University of Maryland Institutional Animal Care and Use Committee.

BMMDs were prepared as previously described (14, 15). Briefly, bone marrow was flushed from the femurs and tibias of mice at 6–10 wk of age. The cells were plated in petri dishes in DMEM/F12 supplemented with 10% FBS, glutamine, penicillin/streptomycin, and 10% conditioned medium from L-929 cells. Cells were fed on days 2 and 5. On day 7, macrophages were removed from petri dishes and cultured on tissue culture dishes in complete medium without L. cell-conditioned medium. Cells were used for the next day. Bone marrow-derived DCs (BMDCs) were generated as previously described (16) with minor modifications. Briefly, bone marrow was prepared as described above. The cells were plated in petri dishes in RPMI 1640 complete medium and 10% conditioned medium from GM-CSF–producing 1588L cells. On days 3 and 6, half of the medium was removed and replaced with fresh conditioned medium. On day 8, the suspension cells were harvested for experiments.

Reagents

TLR ligands were obtained from InvivoGen (San Diego, CA). The p38 inhibitors SB203580, SB203581, and the structurally related control compound SB202474 were purchased from Calbiochem/EMD Biosciences (San Diego, CA). The p38 inhibitors alone or in combination with SB203580 were added to L.929 cells. Cells were fed on days 2 and 5. On day 7, macrophages were removed from petri dishes and cultured on tissue culture dishes in complete medium without L. cell-conditioned medium.

Measurement of cytokine and NO production

Approximately 2 × 10^6 cells were plated per well overnight in a 48-well plate in DMEM/F12 medium with 10% FBS. Cells were then washed and activated with 10 ng/ml LPS. Supernatants were harvested at different times. Cytokines (IL-12/IL-23p40, IL-10, TNFα) were measured by a sandwich ELISA using Ab pairs provided by BD Biosciences (San Diego, CA), according to the manufacturer’s instructions. NO production was assayed by measuring the accumulation of NO3− in the medium of macrophages 24 h after stimulation using the Griess reagent as described previously (17).

Generation of small interfering RNA and cell transfections

A SignalSilence p38 MAPK small interfering RNA (siRNA) kit (Cell Signaling Technology) was used to reduce endogenous p38 protein expression. For cell transfections, 5 × 10^5 primary BMMDs were transfected on day 6 with 100 nM siRNA using Nucleofection technology from Amza (Lonza Walkersville, Walkersville, MD) and then stimulated 48 h later. Gene silencing was confirmed by Western blotting and quantitative real-time RT-PCR.

Western blotting

A total of 2 × 10^6 BMMDs per well were plated overnight in 6-well plates. Cells were treated with 10 ng/ml LPS in a final volume of 1 ml of DMEM/F12. Cells were then lysed in ice-cold lysis buffer (100 mM Tris [pH 8], 2 mM EDTA, 100 mM NaCl, 1% Triton X-100) containing complete EDTA-free protease inhibitors from Roche Diagnostics, which included 5 mM sodium vanadate, 10 mM sodium fluoride, 10 mM β-glycerophosphate sodium, and 5 mM sodium pyrophosphate. Equal amounts of protein were loaded onto 10% SDS-polyacrylamide gels and then transferred to polyvinylidene difluoride membranes. Membranes were incubated with primary Abs overnight at 4°C, washed, and incubated with secondary Ab with HRP conjugates. The specific protein bands were visualized by using a Lumi-LightPLUS chemiluminescent substrate (Roche Diagnostics).

RNA isolation and RT-PCR

TRizol reagent was used to extract RNA from BMMDs (3–4 × 10^6 cells/reaction). Homogenization was conducted to facilitate RNA extraction from footpads and lymph nodes. RNase-free Dnase I was used to remove contaminating genomic DNA. ThermoScript RT-PCR system (Invitrogen) was used to generate cDNA from DNA-free RNA by using random hexamers or oligo(dT), Quantitative real-time PCR was used to measure both mature and premature 112p40 mRNA levels. Premature 112p40 mRNA was analyzed by using random hexamer-generated cDNA and the primer pairs: sense, 5′-TCTGACACTCATCACACTCTG-3′ (intronic primer) and antisense, 5′-GGCAATAAGTTGTTTCTG-3′; and GAPDH primer pairs: sense, 5′-TTGGTGGCAAAATCCTACCT-3′ and antisense, 5′-TTGATGCCAATACACTT-3′. The primers to amplify other genes were: mta-1 primer pairs: sense, 5′-GAACTGGTGAGTCCCGTCTGCTCT-3′ and reverse primer, 5′-CCACACGGAACAAACACACACCT-3′; p38β (mapk14) primer: forward primer, 5′-GACCTCTTGTTACCCCG-3′ and reverse primer, 5′-CTCTAATGTCGCAACACC-3′; p38β (mapk11) primer: forward primer, 5′-AACGACTTGTCGAAACACC-3′ and reverse primer, 5′-TTGCTGACACCTGATGTC-3′; and reverse primer, 5′-GICTACACCTTTGCTTACC-3′ and reverse primer, 5′-GTTGACACCTGATGTT-3′.

Ag priming, challenge studies, and parasite quantitation

BMMDs (0.5 × 10^6/well) derived from BALB/c mice were incubated with OVA protein (100 μg/ml), OVA plus CpG (10 ng/ml) with SB202474 (5 μM), and OVA plus CpG (10 ng/ml) with SB203580 (5 μM) overnight. Supernatants were collected to detect cytokine production, and cells were washed with PBS twice. The treated macrophages were then incubated with the purified CD5+ T cells that were obtained from splenocytes of DO10.11 mice by a negative selection kit according to the instruction supplied by the manufacturer (R&D Systems, Minneapolis, MN). Supernatants were collected 72 h later to detect cytokine production. For vivo studies, OVA (25 μg) and CpG (0.5 μg) were mixed with either 20 μM SB203580 (MAPK/p38 inhibitor) or SB202474 (control compound) in a final volume of 25 μl. The skin lesion was measured 7 d later. Lesion size was determined using the following formula:

\[ \text{Lesion size} = \pi \times r^2 \]

where r is the radius of the lesion.

Generation of small interfering RNA and cell transfections

A SignalSilence p38 MAPK small interfering RNA (siRNA) kit (Cell Signaling Technology) was used to reduce endogenous p38 protein expression. For cell transfections, 5 × 10^5 primary BMMDs were transfected on day 6 with 100 nM siRNA using Nucleofection technology from Amza (Lonza Walkersville, Walkersville, MD) and then stimulated 48 h later. Gene silencing was confirmed by Western blotting and quantitative real-time RT-PCR.

Real-time PCR was conducted with the Roche LightCycler 480 sequence detection system (Roche Diagnostics) using iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) following the manufacturers’ instructions. The relative differences among samples were determined using the ΔΔCT methods as previously described (14, 15). The Ct value for GAPDH gene was used to normalize loading in the RT-PCRs. A ΔΔCT value was then obtained by subtracting control ΔCT values from the corresponding experimental ΔCT. The ΔΔCT values were converted to fold difference compared with the control by raising 2 to the ΔΔCT power. An unpaired Student t test was used for statistical analysis. The p values < 0.05 were considered to be statistically significant.

Results

MAPK/p38 inhibition has reciprocal effects on the production of IL-12 and TNF-α

The ligation of TLRs on macrophages can promote the production of proinflammatory cytokines, including IL-12p40 and TNF-α. It

THE INHIBITION OF IL-12 PRODUCTION BY THE p38 MAPK
has previously been shown that the MAPK p38 plays a positive role in promoting TNF-α production by stimulated macrophages (18). We examined the effect that MAPK/p38 activation has on IL-12p40 production. Macrophages were stimulated with the TLR4 ligand LPS (10 ng/ml) in the presence or absence of the MAPK/p38 inhibitor SB203580. As expected, LPS induced the production of both TNF-α and IL-12p40 from BMMFs. Inhibition of MAPK/p38 by SB203580 resulted in a dose-dependent increase in IL-12p40 production (Fig. 1A). TNF-α production, in contrast, was decreased in a similar dose-dependent manner (Fig. 1A). Similar results were found when a second-generation MAPK/p38 inhibitor designated SB239063 was used (data not shown). The inhibition of MAPK/p38 activation by SB203580 was examined by Western blot analysis (Fig. 1B). LPS stimulation of macrophages resulted in the phosphorylation of both MAPK/p38 and its downstream substrate MK2 (Fig. 1B, left). Both p38 and MK2 activation were detected as early as 10 min after stimulation, reaching maximum levels at 30 min, and persisting for 90 min. Treatment of cells with SB203580 did not affect the levels of phosphorylated p38, as expected, but it inhibited the enzymatic activity of p38 and blocked the phosphorylation of its downstream kinase MK2 (Fig. 1B).

To test whether MAPK/p38 inhibition-induced IL-12p40 production was unique to TLR4 stimulation, we stimulated macrophages with a variety of stimuli, including CpG (Fig. 1C), lipoprotein A (Fig. 1D), or flagellin (Fig. 1E), which are ligands for TLR9, TLR2/TLR6, and TLR5, respectively. All of the TLR agonists tested were able to induce TNF-α and IL-12p40 production from macrophages, and in all cases SB203580 displayed similar effects on cytokine production, increasing IL-12p40 in a dose-dependent manner. The total amount of cytokine induced by these different TLR agonists varied, but the extent of MAPK/p38-mediated IL-12 enhancement and TNF inhibition was comparable. Thus, these data indicate that MAPK/p38 activation can influence IL-12p40 in response to a variety of stimuli.

To determine whether this phenomenon was specific to BMMFs, we carried out similar experiments using resident peritoneal macrophages and BMDCs. Following stimulation with LPS, SB203580 increased IL-12p40 production from BMMFs (Fig. 1F), resident peritoneal macrophages (Fig. 1G), and BMDCs (Fig. 1H). In BMDCs, MAPK/p38 inhibition also enhanced LPS-induced IL-12p70 production (Fig. 1I). For all of these studies, the control compound SB202474 (open circles) failed to influence cytokine production. A similar increase in IL-12p70 production occurred in IFN-
γ-primed LPS-stimulated macrophages treated with SB203580 (data not shown). Therefore, these data show that MAPK/p38 inhibition enhanced IL-12 production, and they suggest that activation of the MAPK/p38 pathway plays a negative regulatory role in IL-12 production by APCs.

**MAPK/p38 inhibition increases IL-12 production due to enhanced p40 mRNA stability**

To determine the cytokine subunit affected by MAPK/p38 inhibition, we examined p35 as well as p40 mRNA production in IFN-γ-primed LPS-stimulated macrophages. IL-12p40 mRNA was increased in the presence of SB203580 (Fig. 2A), whereas the p35 subunit remained essentially unchanged (Fig. 2B). We also examined mRNA encoding the p19 subunit of IL-23, which remained essentially unchanged by the addition of SB203580 (data not shown). We therefore focused on the regulation of the p40 subunit. To gain further insight into the molecular mechanisms of iii2p40 gene expression by MAPK/p38, we investigated changes in ili2 transcription. Nuclear prespliced mRNA (pre-mRNA) and cytoplasmic mature mRNA were isolated following stimulation of macrophages with LPS and measured by real-time PCR as previously described (14). Pre-mRNA expression quickly reached maximal levels at 1 h after LPS stimulation and returned to basal levels by 4 h (Fig. 2C, solid line). IL-12p40 mature mRNA induced by LPS peaked between 1 and 2 h after stimulation and returned to basal levels between 4 and 6 h (Fig. 2D, solid line). Interestingly, p38 inhibition by SB203580 inhibited initial ili2p40 transcription (Fig. 2C, dashed line) but enhanced mature p40 mRNA formation (Fig. 2D, dashed line). As p38 inhibition had a positive effect on IL-12p40 mRNA accumulation but not on transcription, we studied the kinetics of IL-12p40 mRNA degradation in detail (Fig. 2E). Macrophages were treated with SB203580 (open circles, dashed line) or its drug vehicle (closed circles, solid line) and then stimulated with LPS for 2 h, at which time the transcription inhibitor actinomycin D (10 μg/ml) was added. IL-12p40 mRNA degradation was measured at different times during the next 4 h. In the presence of SB203580, IL-12p40 mRNA was more stable. Its half-life increased by ∼2-fold (Fig. 2E). In contrast, TNF-α mRNA was less stable when p38 was inhibited, and its half-life was reduced ∼2-fold (Fig. 2F). These data indicate that the inhibition of MAPK/p38 resulted in increased IL-12p40 production due to at least in part enhanced mRNA stability.

It is well known that IL-10 can inhibit the transcription and translation of IL-12. Therefore, macrophages derived from IL-10 knockout mice were used to determine whether IL-12 enhancement caused by the inhibition of MAPK/p38 was due to a modulation of IL-10. MAPK/p38 inhibition by SB203580 increased IL-12p40 production by ∼3-fold in IL-10−/− macrophages (Fig. 3A), whereas TNF-α production was significantly reduced by this inhibitor (Fig. 3B). This increase in IL-12 production occurred despite the fact that basal LPS-induced IL-12 production was much higher in IL-10−/− macrophages as compared with the cells derived from control littermates. Similar to our observations in wild-type cells, LPS-induced IL-12p40 mRNA was more stable in the presence of the p38 inhibitor (Fig. 3C), whereas TNF-α mRNA was less stable in treated cells (Fig. 3D). These data indicate that the enhanced production of IL-12 following p38 inhibition occurs independently of IL-10.

**IL-12 production is increased in macrophages deficient in p38 or MKK3**

Four isosforms of MAPK/p38, designated α, β, γ, and δ, have been identified. Our Western blot analysis could only detect the presence of the α form in BMMφs (data not shown). By real-time PCR analysis, p38α mRNA was the dominant mRNA species, exceeding p38β levels by >10-fold. MAPK/p38 and γ mRNA expression were undetectable (data not shown). To examine the role of p38 in IL-12 induction, siRNA specific for p38α were introduced into BMMφs 48 h before cells were stimulated with LPS. The addition of siRNA specific for p38α decreased p38α mRNA expression by 80% by quantitative real-time PCR (Fig. 4A) and protein expression by 60% (Western blotting; Fig. 4A, inset). The knockdown of p38 in primary macrophages resulted in a dose-dependent increase in IL-12 p40 production in response to LPS stimulation (Fig. 4B). At 30 nM siRNA, IL-12p40 production was comparable to cells treated with the SB203580 inhibitor (Fig. 4B). We also examined IL-12 production in mice genetically deficient in the gene encoding MKK3, one of the upstream kinases that activates MAPK/p38 (5). These mice are defective in p38 activation, and therefore the extent of LPS-induced phosphorylation of p38 and MK2 was reduced, compared with the wild-type cells (Fig. 4C). Stimulation of macrophages from MKK3−/− mice with LPS resulted in higher levels of IL-12p40 production (Fig. 4D). Furthermore, when these macrophages were primed with IFN-γ and then stimulated with LPS macrophages from MKK3−/−, mice...
produced more IL-12p40 (Fig. 4E) and p70 (Fig. 4F) than did cells from control littermate mice.

Inhibition of MAPK/p38 activation favors a Th1 immune response

Because we observed that MAPK/p38 inhibition could increase IL-12 production in vitro, we investigated whether such inhibition could promote Th1 immune responses. CpG has been widely used as an adjuvant for protein-based vaccinations (19–21). Therefore, we stimulated macrophages in vitro with OVA protein and CpG in the presence of the MAPK/p38 inhibitor SB203580. OVA itself induced no detectable IL-12, as expected. The addition of CpG with OVA induced nanogram levels of IL-12p40 production by macrophages (Fig. 5A, open bars). It also induced a small but measurable amount of IL-12p70 (Fig. 5A, gray bars). The inhibition of p38 activation by SB203580 strongly increased CpG-induced IL-12 production from macrophages. IL-12p40 (Fig. 5A, open bars) was increased by 10-fold and IL-12p70 (Fig. 5A, gray bars) was even more dramatically increased. T cells derived from D011.10 mice were cocultured with stimulated macrophages for 3 d, and supernatants were collected to look for Th1 or Th2 skewing. Macrophages that had been incubated with OVA plus CpG in the presence of SB203580 elicited more IFN-γ (Fig. 5B, gray bars) and less IL-4 (Fig. 5B, open bars) from D011.10 T cells than did macrophages that had been incubated with OVA and CpG without the inhibitor, indicating enhanced Th1 priming.

FIGURE 3. The effect of MAPK/p38 on IL-12 is independent of IL-10. IL-10−/− macrophages were pretreated with increasing concentrations of SB203580 for 1 h and then stimulated with LPS (10 ng/ml) overnight. Supernatants were harvested, and IL-12p40 (A) and TNF-α (B) production were determined by ELISA. Data represent one of three independent experiments (mean ± SD of triplicates). C and D, IL-10−/− macrophages were pretreated with SB203580 (5 μM) (dashed line, ○) or with saline (solid line, ●) for 1 h, and stimulated with LPS (10 ng/ml) for 2 h. Actinomycin D (10 μg/ml) was added and RNA was isolated at the indicated times. Quantitative real-time PCR was performed to analyze the stability of cytokine mRNA (IL-12p40 [C] and TNF-α [D]). Data represent one of three independent experiments (mean ± SD of triplicates).

FIGURE 4. MAPK/p38 knockdown or MKK3 deletion increases IL-12 production. A, siRNA (10 nM) to p38α or mock siRNA was transfected into BMMΦs by nucleofection, and BMMΦs were cultured for 48 h. Total RNA was isolated and real-time PCR was performed to analyze p38α mRNA. Insert, Cell lysates from siRNA-transfected macrophages were prepared for Western blotting analysis using Ab to p38α and ERK1/2. B, BMMΦs were transfected with mock siRNA for 48 h and treated with LPS (10 ng/ml) overnight. Supernatants were harvested to detect IL-12p40 protein by ELISA. C–F, BMMΦs from control littermates (filled bars) and MKK3 knockout mice (open bars) were primed with IFN-γ (100 U/ml) and then stimulated with LPS (10 ng/ml) overnight. ELISA was performed to detect cytokine production. Data represent one of three independent experiments (mean ± SD of triplicates for ELISA data). The p values were determined by a Student t test. *p < 0.05.
The inhibition of MAPK/p38 enhances CpG adjuvanticity and improves vaccine efficacy

We examined whether the inhibition of MAPK/p38 activation would improve vaccine efficacy and enhance protection against L. major, an intracellular parasite whose clearance is linked to Th1 immunity (21). First, we examined whether macrophages or DCs infected with parasites would respond to SB203580 treatment similarly to uninfected cells. BMMs (Fig. 6A) or BMDCs (Fig. 6B) were treated with increasing concentrations of SB203580 and then infected with increasing multiplicities of infection (MOIs) of L. major parasites in the presence or absence of CpG. In the absence of CpG neither macrophages (Fig. 6A) nor DCs (Fig. 6B) produced IL-12 in response to L. major infection. The addition of CpG to macrophages and DCs induced IL-12p40 and p70 production, respectively. Infection with increasing amounts of L. major parasites caused a slight decrease in CpG-induced IL-12 production (Fig. 6A, 6B, dashed lines), but in all cases the inhibition of MAPKp38 by SB203580 resulted in a dose-dependent increase in CpG-induced IL-12p40 production from macrophages (Fig. 6A) and IL-12p70 production from DCs (Fig. 6B). To determine whether SB203580 treatment interfered with the microbicidal activity of activated macrophages, NO production by activated macrophages was measured. Macrophages were primed in vitro with IFN-γ and then stimulated with LPS in the presence or absence of SB203580. The production of NO by uninfected (Fig. 6C) and L. major-infected (Fig. 6D) macrophages was measured 24 h after LPS stimulation. The inhibition of MAPK/p38 caused only a modest decrease in NO production by activated macrophages, and infection with L. major had no effect on the degree of inhibition. In both infected and uninfected macrophages, treatment with high doses of SB203580 (10 μM) resulted in a modest decrease (<30%) in NO production.

We then examined whether SB203580 had an effect on recall responses of mice that were primed with HKLM and CpG and then re-exposed to HKLM in vivo. Upon recall, mice primed with HKLM and CpG in the presence of SB203580 had significantly higher levels of IL-12p40 (Fig. 6E) and IFN-γ (Fig. 6F) in their serum than did mice primed in the absence of SB203580. Ex vivo IFN-γ production from splenocytes of mice primed in vivo with HKLM and CpG in the presence or absence of SB203580 was also examined (Fig. 6G). Splenocytes from mice that were primed in the presence of SB203580 produced higher levels of IFN-γ upon ex vivo restimulation with HKLM than did splenocytes from mice that were primed in the absence of SB203580. The effect of SB203580 treatment was especially pronounced in mice that had been given two injections with HKLM and CpG plus inhibitor (Fig. 6G, open bars). Taken together, these data suggest that inhibition of MAPK/p38 at the time of Ag priming increases IL-12p40 production and leads to higher amounts of IFN-γ production, indicative of enhanced Th1 responses.

Finally, the capacity of SB203580 to enhance CpG adjuvanticity was tested in a murine model of leishmaniasis (Fig. 7). BALB/c mice were vaccinated twice (1 wk apart) with HKLM and CpG, with or without SB203580. Mice were then infected with live L. major, and lesion progression was monitored over an 8-wk period. As shown in Fig. 7A, control naïve BALB/c mice (filled circles) or...
SB203580 enhances CpG effects to induce a Th1 response. A, BMMs or (B) BMDCs derived from C57BL/6 mice were treated with or without increasing doses of SB203580 for 1 h and then infected without or with L. major parasites at MOIs of 0 (●), 2:1 (○), or 5:1 (●) in the absence or presence of CpG for 16 h. Supernatants were harvested and subjected to ELISA to detect IL-12p40 (A) and IL-12p70 (B) production. C and D, BMMs derived from C57BL/6 mice were primed with IFN-γ (100 U/ml) for 2 h and then infected without (●) or with L. major parasites at MOIs of 5:1 in the presence of SB203580 at increasing dosages for 1 h. The cells were then stimulated with LPS for 24 h and the supernatants were collected. Equal volumes of supernatants were mixed with Griess reagent for 10 min, and NOx accumulation was measured. Values represent the mean ± SD (n = 4 mice/group). The *p values were determined by a Student t test.

Discussion

In this paper, we provide evidence to support the idea that the manipulation of MAPK activation levels can exert a profound effect on APC cytokine production. Specifically, we show that the inhibition of MAPK/p38 activation can result in the hyperproduction of IL-12 by stimulated macrophages and DCs and effect the character of an ensuing immune response. We used two MAPK/p38 inhibitors with different structures, SB203580 and SB239063, to enhance IL-12 production. We also demonstrated that limiting the expression of MAPK/p38 protein by specific siRNAs and using mice with targeted deletions of the activating kinase (MKK3) upstream of p38 had similar stimulatory effects on IL-12 production. APCs pretreated with MAPK/p38 inhibitors skewed Ag-specific T cells to produce more IFN-γ and less IL-4. Thus, this work suggests that MAPK/p38 inhibitors may be applied along with adjuvants to improve vaccines against intracellular pathogens.

Previous studies have indicated that MAPK/p38 can promote inflammation by targeting NF-κB to the promoters of inflammatory genes (22) and by stabilizing inflammatory gene transcripts (18). However, the role of MAPK/p38 activation on IL-12 activity has remained somewhat controversial. In an early report, Salmon et al. (23) reported that SB203580 could enhance LPS-initiated IL-12 production by peritoneal exudate macrophages. Kim et al. (24) recently observed that the deletion of p38α resulted in increased expression of several proinflammatory cytokines, including IL-12p40.
normal levels of IFN-γ to anti-CD3 and anti-CD28 for 48 h. Cells were stimulated with PMA for 5 h, infected mice. Lymph nodes were removed on day 56 and stimulated with LPS-induced IL-12p40 production was enhanced in MK2 deletions in MK2, the kinase directly downstream of MAPK/p38 of p38

The inhibition of MAPK/p38 enhances CpG adjuvant effects to vaccinate against L. major in mice. A, BALB/c mice were injected in the left hind footpad with PBS (●) or HKLM (50 µg) with control CpG oligomers (0.5 µg/ml) (○) or HKLM (50 µg) with SB203580 (20 µM) (▼) or with active CpG (0.5 µg/ml) (▲). Some mice received HKLM, CpG oligomers, and SB203580 (20 µM) (●). Mice were injected twice on day 0 and day 7. On day 30, mice were challenged with 1 × 10^5 L. major metacyclic promastigotes in their right footpad. Footpad lesions were monitored weekly. B, Parasite burdens in infected footpads were determined by limiting dilution assays. One representative experiment of three is shown. C, Cytokine production by lymph node T cells from infected mice. Lymph nodes were removed on day 56 and stimulated with anti-CD3 and anti-CD28 for 48 h. Cells were stimulated with PMA for 5 h, and supernatants were harvested and assayed for IFN-γ and IL-4 by ELISA. Data represent mean ± SD. The p values were determined by a Student t test. *p < 0.05.

However, Kang et al. (25) showed that in macrophages the deletion of p38α had a negative effect on IL-12 production. Furthermore, deletions in MK2, the kinase directly downstream of MAPK/p38α/β (5, 26), resulted in more IL-12 production from LPS-stimulated macrophages (27). MKK3 is the dominant upstream kinase that controls activation of MAPK/p38α kinases (5, 26). Lu et al. (28) reported that IL-12 production was reduced in the “elicited” peritoneal macrophages from MKK3-deficient mice. In the present study, we showed that MAPK/p38 inhibition by SB203580 enhanced IL-12p40 production from macrophages and IL-12p70 production from DCs. Our results are in agreement with the results from a report on MK2^-/- macrophages (27) and a more recent study in which Plasmodium falciparum glycosylphosphatidylinositol or LPS-induced IL-12p40 production was enhanced in MK2^-/- macrophages or SB203580-treated macrophages (29).

The role of MAPK/p38 activation in T cells has been extensively studied (9, 30, 31). Murphy and colleagues (31) reported that CD4^+ T cells without p38α could differentiate into Th1 cells that produce normal levels of IFN-γ. However, they were defective in their response to IL-12 and IL-18 stimulation. The TCR complex-associated kinase Zap70 can phosphorylate p38 to induce the production of IFN-γ. This is controlled by the members of growth arrest and DNA damage-inducible genes family (32). Resting T cells from growth arrest and DNA damage-inducible gene 45α-deficient mice undergo spontaneous activation of p38 without activation of the upstream MAPK kinase (32), whereas DCs from these mice have a diminished p38 activity in response to TLR11 and TLR4 ligands (33).

In the present work, we demonstrate that MAPK/p38 inhibition results in an increased half-life of IL-12p40 mRNA. MK2, a major downstream target of MAPK/p38α, has been implicated in the regulation of cytokine mRNA stability and translation possibly through the modification of mRNA-binding proteins by phosphorylation (18). TNF-α is one of the cytokines whose mRNA is stabilized by the activation of the MAPK/p38-MK2 pathway (8). In the present study, MK2 activation was inhibited by the MAPK/p38 inhibitor, and this resulted in a decrease in TNF-α mRNA half-life, consistent with these previous observations. However, this same treatment resulted in more than a doubling of the half-life of IL-12p40 mRNA. The mechanism for this increased mRNA stability is not known. Tristetraprolin has been identified as a target of MK2 (18, 27, 34). Phosphorylated tristetraprolin binds to the AU-rich region of 3'-mRNA of TNF-α to prevent its degradation (34). A typical AU-rich element has not been definitively identified in the 3'-untranslated region of IL-12p40 mRNA, and thus tristetraprolin may not function on IL-12p40 mRNA as it does with TNF-α or other mRNAs containing AU-rich elements. Akira and colleagues (35) recently reported Zc3h12a accelerates IL-6 mRNA degradation and other genes, including IL-12/23p40 and calcitonin receptor. How the inactivation of MK2 or the inhibition of MAPK/p38 enhances LPS-induced IL-12p40 gene expression via mRNA stabilization will be addressed in future experiments. The MAPK/p38-MK2 pathway can also regulate targets other than tristetraprolin. In the study of P. falciparum glycosylphosphatidylinositol-oligosaccharide IL-12p40 in MK2^-/- macrophages, the enhanced binding of NF-κB to IL-12p40 promoter region and the reduction in the expression of transcriptional repressors GAP-12 and c-Maf were attributed to increased IL-12p40 mRNA expression (29). In our study, IL-12p40 transcription was moderately decreased in the macrophages treated with MAPK/p38 inhibitors, as determined by the production of nuclear pre-mRNA. Furthermore, p38 inhibition actually reduced II12p40 promoter activity in a transient transfection of II12p40 promoter reporter experiments (data not shown). Thus, it is unlikely that the inhibition of these transcriptional repressors accounts for the increased IL-12 production in MAPK/p38 inhibited macrophages.

Several earlier studies have suggested that infection of macrophages or DCs by some strains of Leishmania spp. can induce IL-12 production (36–38), suggesting that the inhibition of MAPK/p38 might favor parasite survival through a mechanism that involves reduced IL-12 production by infected cells (13, 39, 40). Our present studies and those of others indicate that the parasites by themselves were unable to induce IL-12 production from macrophages or DCs. In our hands, L. major-infected cells are less responsive to CpG stimulation and produce reduced amounts of IL-12 (Fig. 6) (15); however, they are no less responsive to p38 inhibition. These infected cells efficiently upregulate IL-12 production in response to treatment with SB203580. We also demonstrate that MAPK/p38 inhibition only minimally affects NO production by activated macrophages, so the improvements seen in vaccinated mice are not due to a direct effect on parasite killing by SB203580-treated macrophages but rather to increased IL-12 production. IL-12 functions as a Th1-skewing cytokine to induce IFN-γ (1, 9). Thus, MAPK/p38 inhibition
would be a potential strategy to modulate the host immunity to vaccines. Indeed, macrophages primed with Ag together with the MAPK/p38 inhibitor skewed T cells to produce more IFN-γ. Thus, p38 inhibitors could potentially be used as coadjuvants to boost cell-mediated immunity and improve vaccines against a variety of intracellular pathogens. In our hands, the inhibition of MAPK/p38 resulted in an enhancement of CpG-induced production of both IL-12p40 and IL-12p70 from macrophages and DCs, respectively. Furthermore, when SB203580 was combined with low-dose CpG, IL-12 production was enhanced and there was an increase in the production of IFN-γ production. This increase appeared to be Ag-specific because a second administration of Ag (Fig. 6E) resulted in higher levels of IFN-γ.

In summary, we examined the influence of MAPK/p38 activation on the production of IL-12 production in stimulated macrophages. We show that cells deficient in p38 produce more IL-12 as a result of an increase in the half-life of IL-12 p40 mRNA. We demonstrate that this increased IL-12 production can influence adaptive immune responses and suggest that manipulating the MAPKs may be a feasible approach to improving vaccines against intracellular pathogens. These studies suggest that inhibitors of MAPK/p38 may also prove effective in atopic diseases where uncontrolled Th2 responses predominate. Different generations of MAPK/p38 inhibitors with more potency and better specificity are being developed (26). Our data suggest that these inhibitors may have several unanticipated applications. We propose that the targeting of MAPK/p38 activation cannot only control unwanted inflammatory response, such as TNF overproduction, but may also improve vaccinations against intracellular microorganisms by increasing IL-12 production.

**Disclosures**

The authors have no financial conflicts of interest.

**References**